Type 2 diabetes mellitus (T2DM) and obesity are metabolic disorders characterized by
excess cardiovascular risk. Glucagon-like peptide 1 (GLP1) receptor (GLP1R) agonists …

Patients with type 2 diabetes are at high risk for development of cardiovascular disease,
including myocardial infarction, stroke, heart failure, and cardiovascular death. Multiple large …

Background The glucagon-like peptide-1 (GLP-1) is a multifaceted hormone with broad
pharmacological potential. Among the numerous metabolic effects of GLP-1 are the glucose …

The discovery of glucagon-like peptide-1 (GLP-1), an incretin hormone with important effects
on glycemic control and body weight regulation, led to efforts to extend its half-life and make …

The incidence and prevalence of diabetes mellitus is rapidly increasing worldwide at an
alarming rate. Type 2 diabetes mellitus (T2DM) is the most prevalent form of diabetes …

Atherosclerosis is a chronic inflammatory disease; unstable atherosclerotic plaque rupture,
vascular stenosis, or occlusion caused by platelet aggregation and thrombosis lead to acute …

Glucagon-like peptide-1, produced predominantly in enteroendocrine cells, controls glucose
metabolism and energy homeostasis through regulation of islet hormone secretion …

The heart has a high rate of ATP production and turnover that is required to maintain its
continuous mechanical work. Perturbations in ATP-generating processes may therefore …

Dipeptidyl-peptidase 4 (DPP4) is a glycoprotein of 110 kDa, which is ubiquitously expressed
on the surface of a variety of cells. This exopeptidase selectively cleaves N-terminal …

The incretin hormone Glucagon-Like Peptide-1 (GLP-1) is best known for its “incretin effect”
in restoring glucose homeostasis in diabetics, however, it is now apparent that it has a …